cancer clinical trials for Myeloma/Plasma Cell Dyscrasia (ONC)
8 Myeloma/Plasma Cell Dyscrasia (ONC) clinical trials found. View a list of all cancer clinical trial types.
-
A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis (AFFIRM-AL)
Current Status: Open
View links and contact information related to this clinical trial -
Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecaptagene Vicleucel CAR-T in Multiple Myeloma Patients
Current Status: Open
View links and contact information related to this clinical trial -
Expanded Access Protocol (EAP) For Subjects Receiving Idecabtagene Vicleucel That Is Nonconforming For Commercial Release
Current Status: Open
View links and contact information related to this clinical trial -
Post Trial Access of Modakafusp Alfa (TAK-573) monotherapy or in Combination for the Treatment of Advanced Multiple Myeloma
Current Status: Closed
View links and contact information related to this clinical trial -
Intermediate-Size Population Expanded Access Program (EAP) for cilta-cel Out-of-Specification (OOS) in Patients with Multiple Myeloma
Current Status: Open
View links and contact information related to this clinical trial -
A Phase 2, Multi-Cohort, Open-Label, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects wth Relapsed and Refractory Multiple Myeloma and in Subjects with High-Risk Multiple Myeloma Having Progressed Within One Year of Initial Treatment (KarMMa-2)
Current Status: Open
View links and contact information related to this clinical trial -
Iberdomide Maintenance Therapy in Patients With Multiple Myeloma
Current Status: Open
View links and contact information related to this clinical trial -
A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
Current Status: Open
View links and contact information related to this clinical trial